CONTERA PHARMA A/S: Financial statements 2014
CVR: 33062214
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2014. In 2014, the company reported a gross profit of DKK -125,656 and a net result of DKK -3,237,004 compared with DKK -4,726,146 the year before. Equity in the 2014 report amounted to DKK 1,683,712. The solvency ratio was 89.6%.
- Gross Profit
- DKK -125,656
- Profit/Loss
- DKK -3,237,004
- Equity
- DKK 1,683,712
- Total Assets
- DKK 1,878,915
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | - | -126 t. | -3.2 mio. | 1.7 mio. | - |
| 2013 | - | -3.4 mio. | -4.7 mio. | 1.7 mio. | - |
| 2012 | - | -3.7 mio. | -4.2 mio. | 6.4 mio. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
As of November 24, 2014, Sang Hoon Kim has joined the board of directors of CONTERA PHARMA A/S.
As of November 24, 2014, Hee Won Yoo has joined the board of directors of CONTERA PHARMA A/S.
As of November 24, 2014, Bobby G Soni has left the board of directors of CONTERA PHARMA A/S.
As of November 24, 2014, Carsten Schou has left the board of directors of CONTERA PHARMA A/S.
As of November 24, 2014, Else Sissel Vorstrup has left the board of directors of CONTERA PHARMA A/S.
As of November 24, 2014, Joseph Donald deBethizy has left the board of directors of CONTERA PHARMA A/S.
As of November 24, 2014, Gunnar Magnus Severus Modee Persson has left the board of directors of CONTERA PHARMA A/S.
CONTERA PHARMA A/S has published its annual report for 2013. Gross profit came to DKK -3,423,079, and the net result was DKK -4,726,146.
About CONTERA PHARMA A/S
CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The board consists of Jae Young Lee (chair), Jee Hun Kim, Paul Ejnar Gremaud Kristjansen and Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802.